Report Sections

See All Reports

  • HP:0007379: Neoplasm of the genitourinary tract
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0007379: Neoplasm of the genitourinary tract

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (0)


    Name (Synonyms) Correlation

    Correlated MeSH Terms (1)


    Name (Synonyms) Correlation
    D014565 Urogenital Neoplasms NIH 1.00

    Correlated HPO Terms (0)


    Name (Synonyms) Correlation

    Clinical Trials

    Navigate: Correlations   HPO

    There is one clinical trial.


    1 Observational Retrospective-prospective Study in Patients With Genitourinary Tumors Presenting COVID-19 Infection (SOGUG-COVID-19)

    The identification of patients with genitourinary tumors who suffer from the infection by the Serious Acute Respiratory Syndrome Corona-Virus 2 (SARS-CoV-2) virus can represent multiple benefits both for themselves and for health professionals and the health system itself. We would be able to know more precisely the clinical evolution of these type of patient, to know their prognosis and being capable to select the most appropriate treatment modality for future pandemics. SOGUG-COVID is an observational prospective-retrospective trial purely epidemiological, that aims to describe the population with genitourinary tumors (urothelial cancer, prostate cancer, testicular cancer and kidney cancer) infected by COrona VIrus Disease 19 (COVID-19) treated in Spanish hospitals, learn about the clinical presentation, therapeutic evolution and prognosis of said intercurrent infectious process, as well as its possible relationship with different clinical and therapeutic factors.

    NCT04578132
    Conditions
    1. Covid19
    2. Genito Urinary Cancer
    MeSH:Urogenital Neoplasms
    HPO:Neoplasm of the genitourinary tract

    Primary Outcomes

    Description: Describe the population infected by COVID-19 with genitourinary tumors (urothelial cancer, prostate cancer, testicular cancer and kidney cancer) treated in Spanish hospitals, know the clinical presentation: Age, gender, cancer type. Categorical variables will be presented as counts and percentages.

    Measure: Baseline characteristics

    Time: Through study completion, average 1 year

    Description: Percentage of patients with complications associated to COVID-19 infection (classified by type and severity)

    Measure: Frequency of complications of COVID-19 intercurrent infection

    Time: Through study completion, average 1 year

    Description: To assess the possible relationship of the different oncological treatments administered to these patients with the clinical evolution of the COVID-19 infection. Complications will be classified by type and severity in groups of patients stratified by the oncological treatment received.

    Measure: Frequency of complications of COVID-19 infection in patients stratified by oncological treatment

    Time: Through study completion, average 1 year

    Description: To specifically assess the impact of COVID-19 infection on the toxicity of immunotherapy treatment (mainly pneumonitis) and the impact of immunotherapy on the evolution of the infectious picture in patients with tumors of genitourinary origin. three different scenarios: during treatment, after treatment and in patients who receive treatment after the infection has passed.

    Measure: Frequency of adverse events related to immunotherapy targeted to cancer (classified by type and severity)

    Time: Through study completion, average 1 year. Measured at 3 scenarios (during treatment, after treatment and therapies indicated after infection has passed)

    Description: To evaluate in patients with Prostate Cancer (PCa) the impact of androgen deprivation therapy (ADT) and new antiandrogenic agents (NAH) with or without corticosteroids on the infection COVID-19 as mean of frequency in complications of COVID-19 infection classified by type and severity

    Measure: Frequency of complications of COVID-19 infection in patients with prostate cancer stratified by anti-androgenic oncological treatment

    Time: Through study completion, average 1 year

    Secondary Outcomes

    Description: To assess the mortality associated with COVID-19 infection in the population with genitourinary tumors. Percentage of patients alive / dead at discharge.

    Measure: COVID-19 mortality rate in patients with genitourinary cancer

    Time: Through study completion, average 1 year

    Description: Evaluate the rate (percentage) of complications that have required hospital admission and / or ICU treatment. Complications will be classified by type and severity and represented as percentage of patients presenting them.

    Measure: COVID-19 complication rate in patients with genitourinary cancer

    Time: Through study completion, average 1 year

    Description: Describe the frequency of asymptomatic or minimally symptomatic COVID-19 infections.

    Measure: Asymptomatic rate

    Time: Through study completion, average 1 year

    Description: delays / modifications in cancer follow-up or treatment regimens. The average delay time and the number of modifications will be evaluated.

    Measure: Frequency of delays/modifications on cancer treatment schedule

    Time: Through study completion, average 1 year

    Description: It is expected to obtain data on time to progression and overall survival of cancer patients, which can be compared with the reference values for each type of tumor pathology

    Measure: Progression free survival in patients with genitourinary tumors that suffered COVID-19

    Time: Through study completion, average 1 year

    Description: It is expected to obtain data on time to progression and overall survival of cancer patients, which can be compared with the reference values for each type of tumor pathology

    Measure: Overall survival in patients with genitourinary tumors that suffered COVID-19

    Time: Through study completion, average 1 year

    HPO Nodes


    HP:0007379: Neoplasm of the genitourinary tract
    Genes 347
    BRIP1 IGF2 FIBP RPS7 FERMT1 VHL MC2R WT1 BAP1 MSH2 PHF21A POLD1 CDH1 RPS20 TFE3 RB1 WRN COL14A1 RPS26 EWSR1 VHL AXIN2 POU6F2 WWOX SOX9 RPS17 APC2 MNX1 CDKN2A TBX18 OPCML RPS15A GPC4 DHX37 LMNA BAX AKT1 HRAS MSH3 NSD1 SRY TP53 HNF1B BUB1 MET SETBP1 EPCAM PTEN TP53 WT1 CTNNB1 MLH1 NAB2 STK11 SUFU BUB1B SDHB REST TGFBR2 TRIP13 SDHD PRCC WNT10A MAD1L1 MCC H19 BRCA1 STAG3 MDM2 FGFR2 VAMP7 REST BARD1 MXI1 TP53 NTHL1 DIS3L2 HNF1A FH WT1 TXNRD2 BRCA2 PTEN AR CDKN2A PIK3CA PMS1 RPS10 TSC1 BUB1 PTEN BRCA2 CDH1 RAD51C TRIP13 PMS2 H19 IDH1 RPL27 SEC23B DLST BRCA1 DICER1 CHEK2 KLLN AKT1 TSC1 PTCH1 TRIM28 RPL11 MAP3K1 GREM1 NOD2 PIK3CA CHEK2 POLD1 CCND1 ATP7A SDHB APC CREBBP BRCA1 BUB1B MRAP BUB1B DOCK8 PTCH1 TP53 STK11 RAD54B IGF2 MRE11 WT1 MLH1 PALB2 BLM DIS3L2 KRAS CDKN1B AURKA RPL15 ALX4 FLCN ADA2 POU6F2 TSC2 GPC4 WT1 GATA4 H19-ICR GPC3 SMAD4 USF3 RAD50 PLA2G2A NR0B1 NF1 ZFPM2 NTHL1 POLE RPL35 SRY SDHAF2 FGFR2 NBN SETBP1 PIK3CA LMNA FIBP WT1 STK11 FAN1 HDAC4 HRAS TSC1 SDHC PIK3CA KLF6 OGG1 WT1 AAGAB PAX6 RNF139 RPL31 FH PMS2 MSH2 C11ORF95 MVK H19-ICR B3GALT6 FLI1 MNX1 AR BRCA2 STAR SEMA4A SDHA PALB2 IDH2 BRCA1 RAD51D FGFR3 DMPK FOXE1 DCC SRY TRIM37 RPL5 RPS27 EXT2 KIF1B PTEN RPS24 RPL35A MLH3 RET PTEN PIK3CA HNF1B KRAS IGF2 GPC3 BCL10 DMRT3 KCNQ1 KANSL1 RPL18 TMEM127 MAX EP300 RAD51 MDH2 MINPP1 MSH6 DICER1 CXCR4 WT1 BMPR1A PALLD WT1 TLR2 FGFR3 CCND1 RNF43 KCNQ1OT1 SETD2 PTCH2 EPHB2 MSH2 MSH3 AR PDGFRL SDHB VHL NRAS GATA1 SDHC DIS3L2 PALB2 CDC73 PIK3CA TSR2 SRC BMPER KIT DLC1 KEAP1 CEP57 RELA AKT1 H19-ICR TRIM28 BMPR1A MLH3 STAT6 BRCA2 FLCN CDKN1C CDC73 KANSL1 FLCN GPC4 MLH1 FH CDKN1B BUB3 GPC3 FN1 CTNNB1 DICER1 PTEN NSD1 EP300 RNASEL ZFHX3 PRKAR1A SLC6A17 MAP3K1 TRIP13 DHH HNF4A CHEK2 H19 STS KRAS SDHD RPS19 RPS29 RPL26 KLLN PTEN FLCN GPC3 MSH6 NNT PIK3CA CDC73 IGF2 PTEN BRCA2 VHL KCNQ1OT1 FGFR3 AKT1 RAD51C TSC2 WT1 MSH6 PTPN12 SLC25A11 MLH3 BRCA2 MSH6 NR5A1 TP53 WT1 TSC2 PTPRJ AKT1 IFNG APC PRKN CDH1 HABP2 RPS28 DHH
    Protein Mutations 0
    SNP 0

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0007379: Neoplasm of the genitourinary tract
    Genes 347
    BRIP1 IGF2 FIBP RPS7 FERMT1 VHL MC2R WT1 BAP1 MSH2 PHF21A POLD1 CDH1 RPS20 TFE3 RB1 WRN COL14A1 RPS26 EWSR1 VHL AXIN2 POU6F2 WWOX SOX9 RPS17 APC2 MNX1 CDKN2A TBX18 OPCML RPS15A GPC4 DHX37 LMNA BAX AKT1 HRAS MSH3 NSD1 SRY TP53 HNF1B BUB1 MET SETBP1 EPCAM PTEN TP53 WT1 CTNNB1 MLH1 NAB2 STK11 SUFU BUB1B SDHB REST TGFBR2 TRIP13 SDHD PRCC WNT10A MAD1L1 MCC H19 BRCA1 STAG3 MDM2 FGFR2 VAMP7 REST BARD1 MXI1 TP53 NTHL1 DIS3L2 HNF1A FH WT1 TXNRD2 BRCA2 PTEN AR CDKN2A PIK3CA PMS1 RPS10 TSC1 BUB1 PTEN BRCA2 CDH1 RAD51C TRIP13 PMS2 H19 IDH1 RPL27 SEC23B DLST BRCA1 DICER1 CHEK2 KLLN AKT1 TSC1 PTCH1 TRIM28 RPL11 MAP3K1 GREM1 NOD2 PIK3CA CHEK2 POLD1 CCND1 ATP7A SDHB APC CREBBP BRCA1 BUB1B MRAP BUB1B DOCK8 PTCH1 TP53 STK11 RAD54B IGF2 MRE11 WT1 MLH1 PALB2 BLM DIS3L2 KRAS CDKN1B AURKA RPL15 ALX4 FLCN ADA2 POU6F2 TSC2 GPC4 WT1 GATA4 H19-ICR GPC3 SMAD4 USF3 RAD50 PLA2G2A NR0B1 NF1 ZFPM2 NTHL1 POLE RPL35 SRY SDHAF2 FGFR2 NBN SETBP1 PIK3CA LMNA FIBP WT1 STK11 FAN1 HDAC4 HRAS TSC1 SDHC PIK3CA KLF6 OGG1 WT1 AAGAB PAX6 RNF139 RPL31 FH PMS2 MSH2 C11ORF95 MVK H19-ICR B3GALT6 FLI1 MNX1 AR BRCA2 STAR SEMA4A SDHA PALB2 IDH2 BRCA1 RAD51D FGFR3 DMPK FOXE1 DCC SRY TRIM37 RPL5 RPS27 EXT2 KIF1B PTEN RPS24 RPL35A MLH3 RET PTEN PIK3CA HNF1B KRAS IGF2 GPC3 BCL10 DMRT3 KCNQ1 KANSL1 RPL18 TMEM127 MAX EP300 RAD51 MDH2 MINPP1 MSH6 DICER1 CXCR4 WT1 BMPR1A PALLD WT1 TLR2 FGFR3 CCND1 RNF43 KCNQ1OT1 SETD2 PTCH2 EPHB2 MSH2 MSH3 AR PDGFRL SDHB VHL NRAS GATA1 SDHC DIS3L2 PALB2 CDC73 PIK3CA TSR2 SRC BMPER KIT DLC1 KEAP1 CEP57 RELA AKT1 H19-ICR TRIM28 BMPR1A MLH3 STAT6 BRCA2 FLCN CDKN1C CDC73 KANSL1 FLCN GPC4 MLH1 FH CDKN1B BUB3 GPC3 FN1 CTNNB1 DICER1 PTEN NSD1 EP300 RNASEL ZFHX3 PRKAR1A SLC6A17 MAP3K1 TRIP13 DHH HNF4A CHEK2 H19 STS KRAS SDHD RPS19 RPS29 RPL26 KLLN PTEN FLCN GPC3 MSH6 NNT PIK3CA CDC73 IGF2 PTEN BRCA2 VHL KCNQ1OT1 FGFR3 AKT1 RAD51C TSC2 WT1 MSH6 PTPN12 SLC25A11 MLH3 BRCA2 MSH6 NR5A1 TP53 WT1 TSC2 PTPRJ AKT1 IFNG APC PRKN CDH1 HABP2 RPS28 DHH
    Protein Mutations 0
    SNP 0

    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook